Lamivudine Teva Pharma

Lamivudine, the active ingredient in Lamivudine Teva Pharma, is a nucleoside reverse transcriptase inhibitor presented as a tablet for oral use. It inhibits viral replication and is used to treat HIV infection and chronic hepatitis B in adult patients, often as part of combination therapy.

GNH USA supplies Lamivudine Teva Pharma as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels.

Lamivudine is an antiretroviral nucleoside analogue used in the management of viral infections that affect the immune system and liver.

HIV-1 infection (combined therapy): suppresses viral replication and reduces plasma viral load. HIV-2 infection (combined therapy): provides similar viral suppression in patients infected with HIV‑2. Chronic hepatitis B infection: inhibits hepatitis B virus DNA synthesis, helping to control viral replication and liver disease progression.

Lamivudine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Headache - Fatigue - Diarrhea

Serious or Rare Side Effects: - Lactic acidosis - Severe hepatomegaly with steatosis - Pancreatitis

When prescribing lamivudine, clinicians should consider several safety measures.

Monitor liver function: perform baseline and periodic liver enzyme tests. Assess renal function: adjust dosing in patients with impaired kidney function. Check for hepatitis B co‑infection: monitor viral load and liver status. Avoid in patients with known hypersensitivity to lamivudine or other NRTIs. Pregnancy considerations: use only if potential benefit justifies potential risk, as safety data are limited. Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Lamivudine interacts with several medicines that may alter its efficacy or safety.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis when co‑administered. - Stavudine: heightened risk of lactic acidosis and hepatic steatosis. - Tenofovir: combined use may exacerbate renal toxicity.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce lamivudine plasma concentrations, decreasing efficacy. - Antacids containing aluminum or magnesium: can impair absorption; separate dosing recommended. - Warfarin: potential alteration of INR; monitor coagulation parameters.